163P Combinatorial drug screen identifies therapeutic vulnerabilities of pancreatic cancer subtypes
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Pancreatic ductal adenocarcinoma (PDAC) is highly lethal with few effective treatments, partly due to pronounced tumour heterogeneity and rapid drug resistance. Innovative combination therapies are required to improve clinical outcomes.
Fields of Study & Subjects
Pancreatic and Hepatic Oncology Research
Pancreatitis Pathology and Treatment
Cancer Genomics and Diagnostics
Publication details
- Journal / source
- ESMO Open
- Volume
- 11
- Pages
- 106170–106170
- Publication date
- 1 April 2026
- Language
- EN